Compare BOH & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | WVE |
|---|---|---|
| Founded | 1897 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | N/A | 2015 |
| Metric | BOH | WVE |
|---|---|---|
| Price | $73.93 | $13.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $72.00 | $29.94 |
| AVG Volume (30 Days) | 281.2K | ★ 4.0M |
| Earning Date | 01-26-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $677,459,000.00 | $109,230,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $8.26 | $16.20 |
| P/E Ratio | $18.10 | ★ N/A |
| Revenue Growth | 8.56 | ★ 103.75 |
| 52 Week Low | $57.45 | $5.28 |
| 52 Week High | $76.00 | $21.73 |
| Indicator | BOH | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 44.14 |
| Support Level | $69.95 | $13.22 |
| Resistance Level | $72.40 | $15.97 |
| Average True Range (ATR) | 1.69 | 1.39 |
| MACD | 0.23 | -0.42 |
| Stochastic Oscillator | 88.34 | 5.25 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.